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examination and transrectal ultrasound, CT and/or bone scan 
imaging. Increasingly, multiparametric magnetic resonance 
imaging (mpMRI) is being used to identify the presence, size and 
location of dominant intraprostatic lesions (DIL) for novel 
treatment approaches, such as MR-dose painted brachytherapy. 
This study was done to determine how frequently risk assessment 
was changed after mpMRI and to summarize the dosimetric data 
of DIL coverage for MR-dose painted brachytherapy. 
Methods and Materials: This study was conducted as a 
retrospective chart audit. Staging information, dosimetric data 
and demographics were collected from the electronic patient 
record for prostate cancer patients who had mpMRI staging prior 
to radiotherapy. Pre- and post-mpMRI risk assessment and 
dosimetric data were analyzed using descriptive statistics. 
Univariate analyses of demographic and staging information were 
done to identify factors associated with changes in risk 
assessment. 
Results: In total, 100 patients underwent mpMRI staging. Before 
mpMRI, 12 patients were assessed with low-risk, 47 with 
intermediate- and 41 with high-risk disease. After mpMRI, risk 
assessment changed for 11 patients; four low-risk patients 
changed to intermediate-risk and one low- and six intermediate-
risk patients changed to high-risk. On average, reclassified 
patients had a larger prostate volume (Mean = 48.4cc, StDev = 
10.6 versus Mean = 37.1 cc, StDev = 12.1; p = 0.004). Most 
patients (90/100) had a DIL identified as PiRADs 4 or 5 with an 
average volume of 5.4 cc. The mean boost D90% and V150% to 
the DIL were 131 and 69 respectively. 
Conclusions: Risk assessment changed after mpMRI in a small but 
significant proportion of the patients reviewed in this study. 
mpMRI is an important tool for the identification of intraprostatic 
lesions and the accurate staging of prostate cancer patients prior 
to HDR brachytherapy. 
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Purpose: To validate the Hilts et al. (Brachytherapy 
2015;14:970-8) skin dose to 0.2 ccs’ as a metric to estimate skin 
toxicity following breast brachytherapy with a permanent seed 
implant. 
Methods and Materials: Between November 2013 and December 
2015, 25 patients were treated with a permanent Palladium Seed 
Implant breast brachytherapy technique 14 to 16 weeks following 
breast conserving surgery for Stage 0-1 breast cancer. Prescribed 
dose was 90Gy. Pre-op planning parameters were (PTV V100 > 
95%, V200 < 40%, skin dose to 1 cm2 was kept to < 90% of 
prescribed dose). Immediately following the implant (Day 0 CT) 
patients had a CT simulation performed to assess the implant 
quality. Images were transferred to the Mim Symphony 
treatment planning system and deformably registered to the pre-
op plan to create a post op plan. The deformed seroma contour 
was modified by the treating physician where necessary, and 
doses to skin and PTV were evaluated. PTV V200 and CTV V100 
were calculated. Skin dose to 0.2 cc was calculated and 
correlated with clinical signs and symptoms. Cosmetic outcomes 
were evaluated at 2, 4, 8, 16, 26 and 52 weeks post treatment 
using patient reports based on the Harvard Cosmetic Criteria. 
Results: Mean post-op CTV V100 and PTV V200 were 93.2 Gy and 
36.2 Gy with a range of 70.2 Gy to 100 Gy and 15.8 – 62.4 Gy, 
respectively. Mean dose to 0.2 cc of skin was 51.5 Gy with a range 
of 12.2 Gy to 137.2 Gy. At two and four weeks all but one patient 
had excellent cosmesis. At eight weeks, 17, two and one patients 
reported excellent, good, and fair cosmesis. The patient who 
reported fair continued to score fair until 52 weeks at which time 
she reported good. The two patients that scored “good” had 
Grade 1 reaction and by 16 weeks converted back to excellent. 
All patients who scored “excellent” at 16 weeks continued to 
report excellent on their subsequent visits. Only two patients had 
a skin 0.2 cc dose of > 100 Gy and both reported skin reactions 
(Grade 1 for SD 0.2 cc 137.2, and Grade 2 for SD 0.2cc of 108.1 
Gy). One patient with a 0.2 cc skin dose of 34.8 Gy also 
developed a Grade 1 skin reaction. 
Conclusions: Permanent Breast Seed Implant brachytherapy 
delivered in a single fraction caused a low rate of early side 
effects and patient reported cosmetic results were good to 
excellent in this small group of patients. An SD 0.2cc of > 100 Gy 
appeared to predict skin reactions, as only one out of  23 
reported Grade 1 reaction below this level and two out of two 
patients with a dose above this had skin reactions. Further follow 
up is ongoing to assess late effects and dosimetric factors that 
may predict favourable and less favourable outcomes. More data 
is needed to better predict these factors. 
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Purpose: To extend follow up of a published analysis examining 
the value of the intent to include the internal mammary nodes 
(IMN) in patients with breast cancer receiving adjuvant 
locoregional radiation therapy (RT) to the breast or chest wall 
plus axillary/supraclavicular nodes. 
Methods and Materials: 2413 women with node-positive or 
T3/4pN0 breast cancer, treated with locoregional RT from 2001 
to 2006, were identified using a prospectively maintained, 
population-based database. Intent to include IMN was 
determined by review of charts and RT plans. Kaplan-Meier 
distant relapse-free survival (DRFS), breast cancer specific 
survival (BCSS), and overall survival (OS) were compared 
between the IMN and no-IMN RT groups. Pre-specified subgroup 
analyses of patients with pN1 disease were performed. 
Propensity scores were used to adjust for imbalances in patient, 
tumour, and treatment factors between the two groups. 
Results: Median follow up time was 11.7 years. Forty-one 
percent of subjects received IMN RT. Twelve-year survival 
outcomes among the IMN and no-IMN groups were: DRFS 72.3% 
versus 72.3%, p = 0.85, BCSS 76.4% versus 72.5%, p = 0.41, and 
OS 69.6% versus 63.2%, p = 0.005. Corresponding survival 
comparisons restricted to the pN1 subgroup were: DRFS 83.3% 
versus 80%, p = 0.17, BCSS 86.2% versus 82.7%, p = 0.11, and OS 
79.1% versus 70.5%, p = 0.0003. After adjusting for potential 
confounding factors, the IMN RT group did not have significantly 
different DRFS (hazard ratio [HR] 1.01 (95% confidence interval 
[CI], 0.85-1.19; p = 0.95), BCSS (HR 0.97 (95% CI, 0.81-1.17; p = 
0.77), or OS (HR 0.95; 95% CI, 0.82-1.11; p = 0.53) compared to 
the no-IMN RT group. In the pN1 subgroup, IMN RT was associated 
with non-significant trends for improved survival: DRFS (HR 0.84; 
95% CI, 0.63-1.11; p=0.22), BCSS (HR 0.84; 95% CI, 0.61 -1.14; p 
= 0.26), and OS (HR 0.80; 95% CI, 0.63-1.02; p = 0.08).  
Conclusions: With extended 12-year follow up, the intent to 
include IMN was not associated with significant improvements in 
survival. The survival hazard ratios associated with IMN RT among 
the pN1 cohort, while not statistically significant, appeared 
comparable to those reported in randomized trials, suggesting 
that IMN RT may contribute to improved outcomes in this 
subgroup.  
 
 
 
